Background

Gram-negative *Neisseria meningitidis (N.men)* is an important contributor to bacterial meningitis. Of the estimated 1.2 million cases which occur each year (WHO Figures), N.men is thought to be responsible for around 40% of the total where 5 main serogroups ACWY and B are responsible for the majority of disease.

Conjugated vaccines to prevent *meningococcal* disease have had successful impact especially in the United Kingdom (serogroup C, implemented 1999). In 2005, a newer quadrivalent conjugated vaccine with protection against ACWY serogroups, Menactra (MCV4) was recommended for use in US adolescents. To expand the market further new ACWY conjugated vaccines such as Nimenrix (GSK, EU approved), Menveo (Novartis, FDA approved) and also Menactra (Sanofi Pasteur) have been aiming for use in infants/toddlers as well as further EU schedule inclusion to emulate adolescent recommendations in Greece and Austria. The competitive situation could also take a new turn after the announcement (April 2014) that GSK Biologicals will acquire the vaccines business of Novartis (excluding influenza vaccines).

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume\(^1\) (000s) forecast for all conjugated and unconjugate ACWY products within all age groups indications in the critical US market, EU5, LATAM and MENA regions for the next 10-15 years. The model includes BASE/HI forecast scenarios so the user can visualize the commercial impact of differing recommendation/competitive and pricing scenarios. The analysis also gives a latest review of disease epidemiology.

\(^1\) For primary and booster doses
Methodology

Using currently available information regarding the profile and predicted deployment of a MenACWY/CY prophylactic vaccines, **VacZine Analytics** has modelled potential vaccine demand (mio doses) and revenue estimate ($ 000s) scenarios. The provided model also gives estimates of market share per development company and includes adjustable inputs of vaccine penetration, number of doses and pricing.

**VacZine Analytics** has closely monitored all significant source material pertaining to MenACWY epidemiology/vaccines. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** has also been utilised.

PRODUCT CONTENTS:

**Published July 2014 (CAT No: VAMV009)**

This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Authors note  
Executive summary  
Objectives  
ACWY vaccine global sales per scenario to 2035  
ACWY vaccine global sales by country to 2035 (hi scenario)  
ACWY vaccine global sales per product to 2035 (hi scenario)  
ACWY vaccine US volume per segment to 2035 (hi scenario)  
ACWY vaccine global sales per country to 2035 (base scenario)  
Meningococcal vaccines: company portfolio analysis  
Meningococcal vaccines: portfolio analysis (cont.)  
Meningococcal vaccines: market development  
Meningococcal vaccines: market development - Menomune  
Meningococcal vaccines: market development - Menactra  
Meningococcal vaccines: market development - Menevo  
Meningococcal vaccines: market development – All sales 2004-13  
Meningococcal vaccines: market development – Sales per vaccine, 2013  
Meningococcal vaccines: market development – Sales per country/region, 2013  
Manufacturers and product characteristics: conjugated ACWY vaccines  
Manufacturers and product characteristics: unconjugated ACWY vaccines  
Novartis/GSK deal - portfolio synergy/overlap  
ACWY vaccines  ACWY market segments  
Disease background  
Market segments for ACWY vaccines  
Adolescent markets for ACWY vaccines  
Infant market for ACWY vaccines  
Travellers market for ACWY vaccines  
At risk market for ACWY vaccines
Continued.....

About VacZine Analytics
Disclaimer

PAGES: 85 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet
Charts
Global value (all vaccines)
Global value (Menactra)
Global value (Menveo)
Global value (Nimenrix)
Global value (unconj ACWY)
Global volume
US
EU =>
UK
Germany
France
Italy
Spain
France
LATAM
Chile
Argentina
Brazil
MENA
Saudi Arabia
Other GCC states
Hajj
Source material
Price summary
Hajj visits
Country database
Income groups
Company reported sales
Travel analysis
Travel database
UK Epi
Population databases
Back page
About VacZine Analytics
Disclaimer

WORKSHEETS: 45
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- **USD $8995.00/ GBP £5290.00** (Region license)*

*A region is North America, Europe or ROW

# Indicative rate only. Prevailing rate applied to date of transaction.

For orders in the UK, VAT at 20% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

---

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
Bibliography

TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.

2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.

3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.

4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.

5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.

6. If not purchased on line invoices are payable within thirty days of the invoice date.

7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.

8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.

9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009